Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 224,884,399 papers from all fields of science
Search
Sign In
Create Free Account
adozelesin
Known as:
(7bR,8aS)-N-(2-((4,5,8,8a-Tetrahydro-7-methyl-4-oxocyclopropa(c)pyrrolo(3,2-e)indol-2(1H)-yl)carbonyl)indol-5-yl)-2-benzofurancarboxamide
, 6-(3-methoxy-1-methyl-3-oxo-1-propenyl)-3-methyl-2-cyclohexene-1-carboxylic acid methyl ester
An alkylating agent that bind to the DNA minor groove in a sequence-specific manner and form covalent adducts with adenines, resulting in the…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
5 relations
Broader (4)
Antineoplastic Agents, Alkylating
Cyclohexanecarboxylic Acids
Cyclohexenes
Indoles
Narrower (1)
U 73975
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
Pharmacogenomic analyses of targeting the AT-rich malaria parasite genome with AT-specific alkylating drugs.
J. Woynarowski
,
M. Krugliak
,
H. Ginsburg
Molecular and biochemical parasitology (Print)
2007
Corpus ID: 45866625
2006
2006
S-phase arrest by reactive nitrogen species is bypassed by okadaic acid, an inhibitor of protein phosphatases PP1/PP2A.
P. Ranjan
,
N. Heintz
Free Radical Biology & Medicine
2006
Corpus ID: 21115279
2004
2004
A novel class of achiral seco-analogs of CC-1065 and the duocarmycins: design, synthesis, DNA binding, and anticancer properties.
Stanley Kupchinsky
,
S. Centioni
,
+14 authors
Moses Lee
Bioorganic & Medicinal Chemistry
2004
Corpus ID: 35414182
Highly Cited
2003
Highly Cited
2003
Comparison of checkpoint responses triggered by DNA polymerase inhibition versus DNA damaging agents.
J. Liu
,
S. Kuo
,
T. Melendy
Mutation research
2003
Corpus ID: 46381568
2002
2002
Novel furano analogues of duocarmycin C1 and C2: design, synthesis, and biological evaluation of seco-iso-cyclopropylfurano[2,3-e]indoline (seco-iso-CFI) and seco-cyclopropyltetrahydrofurano[2,3-f…
Tiffany T. Howard
,
B. Lingerfelt
,
+11 authors
Moses Lee
Bioorganic & Medicinal Chemistry
2002
Corpus ID: 34104956
1999
1999
Induction by Adozelesin and Hydroxyurea of Origin Recognition Complex-dependent DNA Damage and DNA Replication Checkpoints in Saccharomyces cerevisiae *
M. Weinberger
,
Peter A. Trabold
,
Michael Lu
,
K. Sharma
,
J. Huberman
,
W. Burhans
Journal of Biological Chemistry
1999
Corpus ID: 25424319
DNA damaging agents induce a conserved intra-S-phase checkpoint that inhibits DNA replication in eukaryotic cells. To better…
Expand
1996
1996
Inhibition of Initiation of Simian Virus 40 DNA Replication in Infected BSC-1 Cells by the DNA Alkylating Drug Adozelesin*
Robert J. Cobuzzi
,
W. Burhans
,
T. Beerman
Journal of Biological Chemistry
1996
Corpus ID: 35026901
Adozelesin is a member of a family of extraordinarily cytotoxic DNA damaging agents that bind to the DNA minor groove in a…
Expand
1994
1994
Mapping of DNA alkylation sites induced by adozelesin and bizelesin in human cells by ligation-mediated polymerase chain reaction.
C. S. Lee
,
G. Pfeifer
,
N. Gibson
Biochemistry
1994
Corpus ID: 38921330
In this study, we have mapped the intracellular alkylation sites of adozelesin and bizelesin, two potent analogs of CC-1065, in…
Expand
1992
1992
Lethality, DNA alkylation, and cell cycle effects of adozelesin (U-73975) on rodent and human cells.
Bijoy K. Bhuyan
,
Kathy S. Smith
,
E. G. Adams
,
G. Petzold
,
J. Mcgovren
Cancer Research
1992
Corpus ID: 12431839
Adozelesin (U-73975) is an extremely potent cytotoxic agent which causes 90% lethality, after 2 h exposure in vitro, of Chinese…
Expand
1991
1991
In vitro and in vivo DNA bonding by the CC-1065 analogue U-73975.
K. L. Weiland
,
T. P. Dooley
Biochemistry
1991
Corpus ID: 24881129
CC-1065, a cyclopropylpyrroloindole (CPI), is a highly potent antitumor DNA-alkylating agent. We have devised a simple method to…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE